• Je něco špatně v tomto záznamu ?

Genetic variation in TNFA predicts protection from severe bacterial infections in patients with end-stage liver disease awaiting liver transplantation

R. Senkerikova, E. de Mare-Bredemeijer, S. Frankova, D. Roelen, T. Visseren, P. Trunecka, J. Spicak, H. Metselaar, M. Jirsa, J. Kwekkeboom, J. Sperl,

. 2014 ; 60 (4) : 773-81.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15023602

BACKGROUND & AIMS: Augmented susceptibility to infections increases mortality in patients with end-stage liver disease (ESLD). We sought to determine the contribution of selected genetic variants involved in inflammatory signalling downstream of the Toll-like receptor 4 (TLR4) to severe bacterial infections (SBIs) in patients with ESLD. METHODS: We retrospectively assessed incidence of SBIs in 336 adult ESLD patients enlisted for orthotopic liver transplantation (OLT) and genotyped them for TLR4 c.+1196C/T, CD14 c.-159C/T, TNFA c.-238G/A, TNFA c.-863C/A, IL1B c.-31C/T and IL1RN variable number of tandem repeats allelic variants. Principal findings were validated in an independent cohort of 332 ESLD patients. RESULTS: Thirty-four percent of patients from the identification cohort and 40% of patients from the validation cohort presented with SBI while enlisted for OLT. The presence of the variant allele TNFA c.-238A (rs361525) was associated with lower serum levels of TNF-α, and with significantly decreased risk of SBI in both cohorts. Multivariate analysis showed that the relative protection from SBI associated with this allele almost completely negated the increased susceptibility to SBI owed to advanced ESLD. Although not predictive of overall mortality, the presence of the TNFA c.-238A allele was associated with a complete prevention of SBI-related pre-transplant deaths. CONCLUSIONS: Our results suggest that genetic variability in inflammatory signalling is associated with the development of SBI in patients with ESLD. Specifically, we identified the importance of the TNFA c.-238A allele as a strong predictor of protection from SBI, and as a genetic marker associated with significantly improved pre-transplant survival in patients with SBI.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023602
003      
CZ-PrNML
005      
20250402154959.0
007      
ta
008      
150709s2014 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jhep.2013.12.011 $2 doi
035    __
$a (PubMed)24361409
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Senkerikova, Renata $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
245    10
$a Genetic variation in TNFA predicts protection from severe bacterial infections in patients with end-stage liver disease awaiting liver transplantation / $c R. Senkerikova, E. de Mare-Bredemeijer, S. Frankova, D. Roelen, T. Visseren, P. Trunecka, J. Spicak, H. Metselaar, M. Jirsa, J. Kwekkeboom, J. Sperl,
520    9_
$a BACKGROUND & AIMS: Augmented susceptibility to infections increases mortality in patients with end-stage liver disease (ESLD). We sought to determine the contribution of selected genetic variants involved in inflammatory signalling downstream of the Toll-like receptor 4 (TLR4) to severe bacterial infections (SBIs) in patients with ESLD. METHODS: We retrospectively assessed incidence of SBIs in 336 adult ESLD patients enlisted for orthotopic liver transplantation (OLT) and genotyped them for TLR4 c.+1196C/T, CD14 c.-159C/T, TNFA c.-238G/A, TNFA c.-863C/A, IL1B c.-31C/T and IL1RN variable number of tandem repeats allelic variants. Principal findings were validated in an independent cohort of 332 ESLD patients. RESULTS: Thirty-four percent of patients from the identification cohort and 40% of patients from the validation cohort presented with SBI while enlisted for OLT. The presence of the variant allele TNFA c.-238A (rs361525) was associated with lower serum levels of TNF-α, and with significantly decreased risk of SBI in both cohorts. Multivariate analysis showed that the relative protection from SBI associated with this allele almost completely negated the increased susceptibility to SBI owed to advanced ESLD. Although not predictive of overall mortality, the presence of the TNFA c.-238A allele was associated with a complete prevention of SBI-related pre-transplant deaths. CONCLUSIONS: Our results suggest that genetic variability in inflammatory signalling is associated with the development of SBI in patients with ESLD. Specifically, we identified the importance of the TNFA c.-238A allele as a strong predictor of protection from SBI, and as a genetic marker associated with significantly improved pre-transplant survival in patients with SBI.
650    _2
$a dospělí $7 D000328
650    _2
$a bakteriální infekce $x genetika $x imunologie $x prevence a kontrola $7 D001424
650    _2
$a kohortové studie $7 D015331
650    _2
$a konečné stadium selhání jater $x komplikace $x genetika $x imunologie $7 D058625
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a frekvence genu $7 D005787
650    _2
$a genetické asociační studie $7 D056726
650    _2
$a genetické markery $7 D005819
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a genetická variace $7 D014644
650    _2
$a lidé $7 D006801
650    12
$a transplantace jater $7 D016031
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a toll-like receptor 4 $x genetika $7 D051197
650    _2
$a TNF-alfa $x krev $x genetika $7 D014409
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a de Mare-Bredemeijer, Emmeloes $u Department of Gastroenterology and Hepatology, Erasmus MC - University Medical Centre, Rotterdam, The Netherlands.
700    1_
$a Fraňková, Soňa $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0329475
700    1_
$a Roelen, Dave $u Department of Immunohematology and Blood Transfusion, University Medical Centre, Leiden, The Netherlands.
700    1_
$a Visseren, Thijmen $u Department of Gastroenterology and Hepatology, Erasmus MC - University Medical Centre, Rotterdam, The Netherlands.
700    1_
$a Trunecka, Pavel $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Spicak, Julius $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Metselaar, Herold $u Department of Gastroenterology and Hepatology, Erasmus MC - University Medical Centre, Rotterdam, The Netherlands.
700    1_
$a Jirsa, Milan $u Laboratory of Experimental Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kwekkeboom, Jaap $u Department of Gastroenterology and Hepatology, Erasmus MC - University Medical Centre, Rotterdam, The Netherlands.
700    1_
$a Sperl, Jan $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address: jan.sperl@ikem.cz.
773    0_
$w MED00010017 $t Journal of hepatology $x 1600-0641 $g Roč. 60, č. 4 (2014), s. 773-81
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24361409 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20250402154955 $b ABA008
999    __
$a ok $b bmc $g 1083939 $s 906595
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 60 $c 4 $d 773-81 $i 1600-0641 $m Journal of hepatology $n J Hepatol $x MED00010017
LZP    __
$a Pubmed-20150709
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace